Humana’s Lawsuit Against Biogen Decries Ongoing ‘Seed and Sweep’ Schemes

Humana’s Lawsuit Against Biogen Decries Ongoing ‘Seed and Sweep’ Schemes

307986

Humana’s Lawsuit Against Biogen Decries Ongoing ‘Seed and Sweep’ Schemes

People living with multiple sclerosis know that the medications used to treat it are expensive. According to the National Multiple Sclerosis Society, the median annual price of brand-name disease-modifying therapies (DMTs) last year was $91,835. Five of them carried a price tag of more than $100,000 a year. Many pharmaceutical companies help defray the out-of-pocket costs of their DMTs for patients. But U.S. law strictly limits how this can be done for people covered by…

You must be logged in to read/download the full post.